Vol. 9, Issue 12, Part H (2025)

The present investigation was undertaken to evaluate the pathomorphological alterations associated with arsenic-induced sub-chronic toxicity in Wistar rats and its amelioration with resveratrol. Thirty-six adult male Wistar rats were randomly divided into six groups (n=6). Group I served as normal control, Group II as disease control (NaAsO₂ @ 10 mg/kg b.wt. orally for 60 days), Group III received treatment same as Group II along with telmisartan (10 mg/kg b.wt. orally for 60 days) as a reference control group and Groups IV-VI received treatment same as Group II along with resveratrol at graded doses (4, 8, and 16 mg/kg b.wt. orally for 60 days). The disease control group exhibited a significant reduction (p<0.05) in body weight, hematological parameters, and alterations in biochemical indices including increased ALT, ALP, BUN, and creatinine with decreased total protein levels. Antioxidant assays revealed significant elevation in lipid peroxidation and depletion of SOD and catalase activities in the disease control group. Treatment with resveratrol and telmisartan ameliorated these changes in a dose-dependent manner. Histopathological examination of the aorta revealed lesions consistent with oxidative stress and inflammation. Special staining of the aorta further demonstrated vascular alterations, which were markedly reduced in the resveratrol (16 mg/kg) and telmisartan-treated groups. The study concludes that resveratrol exhibits potent antioxidant and cytoprotective efficacy against sub-chronic arsenic-induced vascular and systemic toxicity, comparable to telmisartan.